In 208 kidney transplant recipients with chronic allograft dysfunction, dapagliflozin vs placebo for 12 months did not improve eGFR; at 12 months eGFR was higher with placebo (39.4 vs 36.5). Dapagliflozin reduced proteinuria, blood pressure and BMI.
RCTn = 208
David-Neto et al. The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial